Next Article in Journal
The Angiotensin-Converting Enzyme Inhibitor Lisinopril Mitigates Memory and Motor Deficits in a Drosophila Model of Alzheimer’s Disease
Next Article in Special Issue
Metabolomics and EMT Markers of Breast Cancer: A Crosstalk and Future Perspective
Previous Article in Journal
Implication of RAS in Postnatal Cardiac Remodeling, Fibrosis and Dysfunction Induced by Fetal Undernutrition
 
 
Protocol

A Clinical Trial for the Identification of Metabolic Biomarkers in Hashimoto’s Thyroiditis and in Psoriasis: Study Protocol

1
Laboratory of Toxicology and Forensic Sciences, Medical School, University of Crete, 71003 Heraklion, Greece
2
Metabolomic Medicine, Health Clinics for Autoimmune and Chronic Diseases, 10674 Athens, Greece
3
Dermatology Department, University Hospital of Heraklion, 71500 Heraklion, Greece
4
European Institute of Nutritional Medicine, 00198 Rome, Italy
5
Clinic of Endocrinology and Metabolic Disorders, Cantonal Hospital Olten, Baslerstrasse 150, 4600 Olten, Switzerland
*
Author to whom correspondence should be addressed.
Academic Editor: Jonathan Steven Alexander
Pathophysiology 2021, 28(2), 291-306; https://doi.org/10.3390/pathophysiology28020019
Received: 13 May 2021 / Revised: 7 June 2021 / Accepted: 9 June 2021 / Published: 14 June 2021
(This article belongs to the Special Issue Recent Advances in Metabolomics and Applications in Chronic Diseases)
Hashimoto’s thyroiditis and psoriasis are inflammatory disorders that significantly impact patients’ quality of life, stressing the need for novel biomarkers of early diagnosis. This randomized clinical trial (NCT04693936) aims to identify Hashimoto’s thyroiditis’ and psoriasis’ metabolic biomarkers and to investigate the effect of environmental factors on the disease-related metabolic imprint and quality of life. Patients with Hashimoto’s thyroiditis, patients with psoriasis, and healthy individuals aged 18–60 will be recruited, enrolled according to eligibility criteria (medical history, clinical thyroid markers and the PASI score) and randomized to two groups. The intervention group will receive a combination of nutraceuticals for 6 months as part of a Mediterranean diet, and the control group will follow their usual diet. Data will be collected at baseline and the end of the study, including metabolite levels, lifestyle and anthropometric measurements, adherence to the Mediterranean diet (through the Mediterranean Diet Score) and disease-specific quality of life (through the Thyroid Patient Report Outcome for Hashimoto’s group, and the Dermatology Life Quality Index for the psoriasis group). This study will investigate metabolic biomarkers and related changes in Hashimoto’s thyroiditis and psoriasis and evaluate the association of metabolic changes with dietary factors and quality of life. View Full-Text
Keywords: Hashimoto’s; psoriasis; metabolomics; organic acids; fatty acids; metabolic biomarkers; epigenetic factors; quality of life Hashimoto’s; psoriasis; metabolomics; organic acids; fatty acids; metabolic biomarkers; epigenetic factors; quality of life
Show Figures

Figure 1

MDPI and ACS Style

Sarandi, E.; Kruger Krasagakis, S.; Tsoukalas, D.; Rudofsky, G.; Tsatsakis, A. A Clinical Trial for the Identification of Metabolic Biomarkers in Hashimoto’s Thyroiditis and in Psoriasis: Study Protocol. Pathophysiology 2021, 28, 291-306. https://doi.org/10.3390/pathophysiology28020019

AMA Style

Sarandi E, Kruger Krasagakis S, Tsoukalas D, Rudofsky G, Tsatsakis A. A Clinical Trial for the Identification of Metabolic Biomarkers in Hashimoto’s Thyroiditis and in Psoriasis: Study Protocol. Pathophysiology. 2021; 28(2):291-306. https://doi.org/10.3390/pathophysiology28020019

Chicago/Turabian Style

Sarandi, Evangelia, Sabine Kruger Krasagakis, Dimitris Tsoukalas, Gottfried Rudofsky, and Aristides Tsatsakis. 2021. "A Clinical Trial for the Identification of Metabolic Biomarkers in Hashimoto’s Thyroiditis and in Psoriasis: Study Protocol" Pathophysiology 28, no. 2: 291-306. https://doi.org/10.3390/pathophysiology28020019

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop